Zega Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Zega Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,503	Closed	-$628K	–	135
2024 Q1	$628K	Buy	+1,503	New	+$635K	0.22%	57

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Zega Financial's VRTX Position: Q2 2024 in Review

Zega Financial sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 1,503 shares — an estimated $628K sold.

Zega Financial first reported a position in VRTX in Q1 2024 and held it in 1 quarter. The position peaked at $628K in Q1 2024. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

Zega Financial reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Zega Financial sold 1,503 Vertex Pharmaceuticals shares in Q2 2024, an estimated $628K.
Zega Financial first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 1 quarter.
Zega Financial's Vertex Pharmaceuticals position peaked at $628K in Q1 2024.
1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Zega Financial's 13F filing for Q2 2024, filed 12 Aug 2024.